DekaBank Deutsche Girozentrale Boosts Stock Position in BioNTech SE (NASDAQ:BNTX)

DekaBank Deutsche Girozentrale increased its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 12.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 481,397 shares of the company's stock after acquiring an additional 53,800 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.20% of BioNTech worth $56,886,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in BNTX. Mirae Asset Global Investments Co. Ltd. increased its position in shares of BioNTech by 17.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,931 shares of the company's stock valued at $465,000 after purchasing an additional 582 shares during the last quarter. Mount Yale Investment Advisors LLC bought a new position in BioNTech during the third quarter valued at $244,000. International Assets Investment Management LLC purchased a new stake in shares of BioNTech in the third quarter valued at $21,300,000. Slow Capital Inc. lifted its holdings in shares of BioNTech by 1.2% in the 3rd quarter. Slow Capital Inc. now owns 51,680 shares of the company's stock worth $6,138,000 after acquiring an additional 600 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after purchasing an additional 388 shares during the period. 15.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. UBS Group upped their target price on BioNTech from $97.00 to $131.00 and gave the company a "neutral" rating in a research note on Wednesday, September 18th. HSBC lifted their target price on BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. Jefferies Financial Group upgraded shares of BioNTech from a "hold" rating to a "buy" rating and upped their price target for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. HC Wainwright boosted their price objective on shares of BioNTech from $113.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, October 7th. Finally, Morgan Stanley raised shares of BioNTech from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, BioNTech has an average rating of "Moderate Buy" and a consensus target price of $135.54.

BioNTech Stock Up 2.5 %

Shares of BioNTech stock traded up $2.78 on Monday, reaching $113.26. The stock had a trading volume of 666,760 shares, compared to its average volume of 782,553. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $26.92 billion, a P/E ratio of 220.96 and a beta of 0.24. The company has a 50 day moving average price of $107.26 and a 200 day moving average price of $94.98. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. During the same period in the previous year, the company posted ($0.86) earnings per share. The business's revenue for the quarter was down 23.3% on a year-over-year basis. As a group, equities research analysts forecast that BioNTech SE will post -3.04 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.